Literature DB >> 31483510

Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation.

Yoel Angel1, David Zeltser1, Shlomo Berliner1, Merav Ingbir1, Itzhak Shapira1, Shani Shenhar-Tsarfaty1, Ori Rogowski1.   

Abstract

AIMS: To assess whether hospitalization may assist in correcting errors in anticoagulant therapy among patients with atrial fibrillation (AF).
METHODS: Our cohort included patients admitted to our institution with a history of AF between 2016 and 2018. We categorized patient's treatment upon admission and discharge as lacking (no treatment despite indication), inadequate (according to individual characteristics) or adequate. We assessed adequacy of treatment upon discharge and determined factors associated with correcting admission errors.
RESULTS: Of 4427 patients admitted with a history of AF, the categorization to lacking, inadequate and adequate treatment was 1746 (39.4%), 1237 (27.9%) and 1444 (32.6%) patients, respectively. Of those with inadequate treatment, the most common types of errors were direct oral anticoagulant (DOAC) underdosing (n = 578; 46.7%), vitamin-K antagonists when DOAC was indicated (n = 258; 20.9%), DOAC despite contraindication to DOAC (n = 166; 13.4%) and DOAC overdosing (n = 124; 10%). Upon discharge 688 (18.6%, out of n = 3694) corrections but also 316 (8.6%) new mistakes were found. On multivariate logistic regression, the factors associated with correction of an error on admission were hospitalization due to AF (odds ratio [OR] 2.94 [2.39-3.61]), hospitalization in the neurologic or geriatric wards (OR 2.79 [2.04-3.80]), female sex (OR 1.34 [1.10-1.63]) and a history of stroke (OR 1.47 [1.17-1.86]), while the presence of a contraindication to DOAC decreased the chance of correction (OR 0.10 [0.06-0.18]).
CONCLUSION: Hospitalization for any reason may contribute to correction of errors in AC treatment in patients with AF. Unfortunately, a significant portion of patients remains inadequately treated by both outpatient and inpatient providers.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  anticoagulants; cardiovascular; internal medicine; medication errors; stroke

Mesh:

Substances:

Year:  2019        PMID: 31483510      PMCID: PMC6955396          DOI: 10.1111/bcp.14116

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  The lifetime risk of stroke: estimates from the Framingham Study.

Authors:  Sudha Seshadri; Alexa Beiser; Margaret Kelly-Hayes; Carlos S Kase; Rhoda Au; William B Kannel; Philip A Wolf
Journal:  Stroke       Date:  2006-01-05       Impact factor: 7.914

3.  Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.

Authors:  Elaine Nguyen; C Michael White; Manesh R Patel; Larry E Fields; W Frank Peacock; Concetta Crivera; Craig I Coleman
Journal:  Curr Med Res Opin       Date:  2016-04-01       Impact factor: 2.580

4.  Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation.

Authors:  Paul L Hess; Sunghee Kim; Gregg C Fonarow; Laine Thomas; Daniel E Singer; James V Freeman; Bernard J Gersh; Jack Ansell; Peter R Kowey; Kenneth W Mahaffey; Paul S Chan; Benjamin A Steinberg; Eric D Peterson; Jonathan P Piccini
Journal:  Am J Med       Date:  2016-11-23       Impact factor: 4.965

5.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

7.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

Review 8.  Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials.

Authors:  Bruria Hirsh Raccah; Amichai Perlman; Haim D Danenberg; Arthur Pollak; Mordechai Muszkat; Ilan Matok
Journal:  Chest       Date:  2016-01-18       Impact factor: 9.410

9.  Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation.

Authors:  Carlotta Franchi; Stefania Antoniazzi; Marco Proietti; Alessandro Nobili; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

10.  Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program.

Authors:  Amichai Perlman; Ehud Horwitz; Bruria Hirsh-Raccah; Gefen Aldouby-Bier; Tamar Fisher Negev; Sarit Hochberg-Klein; Yosef Kalish; Mordechai Muszkat
Journal:  Isr J Health Policy Res       Date:  2019-02-01
View more
  2 in total

1.  Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis.

Authors:  Abdulrhman Al Rowily; Zahraa Jalal; Malcolm J Price; Mohammed H Abutaleb; Hind Almodiaemgh; Maha Al Ammari; Vibhu Paudyal
Journal:  Eur J Clin Pharmacol       Date:  2021-12-22       Impact factor: 2.953

2.  Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation.

Authors:  Bruria Hirsh Raccah; Yevgeni Erlichman; Arthur Pollak; Ilan Matok; Mordechai Muszkat
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-06-01       Impact factor: 2.457

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.